Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • Nebraska
  • Lincoln


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Using VR to Assess the Efficacy of a Motivational Interviewing Intervention to Increase Bystander Behaviors
    NCT04160702
    Condition:   Sexual Assault
    Intervention:   Behavioral: Motivate-The-Bystander (MTB)
    Sponsors:   University of Nebraska Lincoln;   University of Nebraska
    Recruiting
  • Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects
    NCT04044339
    Condition:   Healthy
    Interventions:   Drug: TD-5202;   Drug: Placebo
    Sponsor:   Theravance Biopharma
    Recruiting
  • Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects
    NCT03830125
    Condition:   Idiopathic Pulmonary Fibrosis
    Interventions:   Drug: BBT-877, Single dose;   Drug: Placebo group;   Drug: BBT-877, Multiple doses
    Sponsors:   Bridge Biotherapeutics, Inc.;   KCRN Research, LLC
    Recruiting
  • A Study to Assess Tobacco-related Biomarkers of Exposure in Smokers Using myBlu E-cigarettes
    NCT04019626
    Condition:   Healthy Volunteers
    Interventions:   Other: Continue-smoking;   Other: myblu Tobacco Chill 2.5%;   Other: myblu Tobacco Chill 4.0%;   Other: myblu Honeymoon 2.5%;   Other: myblu Honeymoon 4.0%
    Sponsor:   Fontem Ventures BV
    Recruiting
  • Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
    NCT03007979
    Conditions:   Breast Cancer;   Breast Carcinoma;   Cancer of Breast;   Malignant Tumor of Breast
    Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Procedure: Optional research biopsy;   Drug: Goserelin;   Procedure: Research blood draw;   Procedure: Circulating tumor cell blood draw;   Procedure: Tumor biopsy (optional)
    Sponsors:   Washington University School of Medicine;   Pfizer
    Recruiting
  • A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
    NCT04032093
    Condition:   Respiratory Tract Infection
    Interventions:   Biological: RSV vaccine;   Biological: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
    NCT04003103
    Condition:   HIV-1 Infection
    Interventions:   Drug: Islatravir;   Drug: Placebo
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology
    NCT03699514
    Conditions:   Healthy;   Cognitive Impairment;   Neurological Disorder
    Intervention:   Device: Brain Network Activation (BNA™) technology
    Sponsor:   ElMindA Ltd
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
    NCT02734537
    Conditions:   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant;   Lip and Oral Cavity Squamous Cell Carcinoma;   p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
    NCT02224781
    Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
    NCT04084769
    Condition:   Meningococcal Infection (Healthy Volunteers)
    Interventions:   Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine;   Biological: Meningococcal Group B Vaccine (Trumenba®);   Biological: Meningococcal group B Vaccine (Bexsero®)
    Sponsor:   Sanofi Pasteur, a Sanofi Company
    Recruiting
  • Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
    NCT02924727
    Condition:   Acute Myocardial Infarction
    Interventions:   Drug: LCZ696 (sacubitril/valsartan);   Drug: Ramipril;   Drug: Placebo of LCZ696;   Drug: Placebo of ramipril;   Drug: Valsartan;   Drug: Placebo of valsartan
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
    NCT02761057
    Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • S0820, Adenoma and Second Primary Prevention Trial
    NCT01349881
    Condition:   Colorectal Neoplasms
    Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
    Recruiting
  • Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
    NCT00632853
    Condition:   Lung Cancer
    Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
    NCT03851445
    Condition:   Previously Treated Non-Small Cell Lung Cancer
    Intervention:   Drug: Screening Platform
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
    NCT03839940
    Condition:   Malignant Neoplasm
    Interventions:   Drug: Dexamethasone;   Other: Placebo;   Other: Questionnaire;   Other: Quality-of-Life Assessment;   Drug: Everolimus
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
    NCT03662204
    Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
    Intervention:   Other: Blood Sample Collection
    Sponsor:   Exact Sciences Corporation
    Recruiting
  • Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
    NCT03578081
    Condition:   Malignant Neoplasm
    Interventions:   Drug: Palonosetron Hydrochloride;   Drug: Ondansetron Hydrochloride;   Drug: Dexamethasone;   Drug: Fosaprepitant Dimeglumine;   Drug: Olanzapine;   Other: Placebo
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
    NCT03510897
    Condition:   Cardiac Surgery
    Interventions:   Drug: QPI-1002;   Drug: Placebo
    Sponsor:   Quark Pharmaceuticals
    Recruiting
  • A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
    NCT03412565
    Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Carfilzomib
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Baroreflex Activation Therapy for Heart Failure
    NCT02627196
    Condition:   Heart Failure
    Interventions:   Device: BAROSTIM NEO® System;   Drug: Medical Management
    Sponsor:   CVRx, Inc.
    Recruiting
  • Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
    NCT00887146
    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: concomitant temozolomide (TMZ);   Radiation: radiotherapy;   Drug: procarbazine;   Drug: adjuvant temozolomide (TMZ);   Drug: CCNU;   Drug: vincristine
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment Center (EORTC);   Canadian Cancer Trials Group
    Recruiting
  • Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
    NCT03893448
    Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
    Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
    NCT04186871
    Conditions:   Autoimmune Disorder;   Rheumatoid Arthritis;   Systemic Lupus Erythematosus;   Primary Sjögren's Syndrome
    Interventions:   Drug: branebrutinib;   Drug: abatacept;   Drug: branebrutinib placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation
    NCT03729830
    Condition:   Paroxysmal Atrial Fibrillation
    Intervention:   Device: Boston Scientific Open Irrigated Ablation Catheters
    Sponsor:   Boston Scientific Corporation
    Recruiting
  • Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer
    NCT04095364
    Conditions:   Low Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal Low Grade Serous Adenocarcinoma;   Stage II Ovarian Cancer AJCC v8;   Stage IIA Ovarian Cancer AJCC v8;   Stage IIB Ovarian Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Drug: Letrozole;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
    NCT04008706
    Condition:   Chronic Lymphocytic Leukemia
    Intervention:   Drug: Acalabrutinib
    Sponsors:   AstraZeneca;   Parexel
    Recruiting
  • Genetic Testing in Guiding Treatment for Patients With Brain Metastases
    NCT03994796
    Conditions:   CDK Gene Mutation;   Metastatic Malignant Neoplasm in the Brain;   Metastatic Malignant Solid Neoplasm;   NTRK Family Gene Mutation;   PI3K Gene Mutation;   ROS1 Gene Mutation
    Interventions:   Drug: Abemaciclib;   Drug: PI3K Inhibitor GDC-0084;   Drug: Entrectinib
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Genentech, Inc.
    Recruiting
  • Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
    NCT03980483
    Condition:   Arthritis, Rheumatoid
    Interventions:   Biological: GSK3196165;   Drug: Tofacitinib 5 mg;   Drug: Placebo to GSK3196165;   Drug: Placebo to tofacitinib;   Drug: Methotrexate;   Drug: Folic (or folinic) acid
    Sponsors:   GlaxoSmithKline;   Iqvia Pty Ltd
    Recruiting
  • Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
    NCT03971474
    Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • An Early Feasibility Evaluation of the AccuCinch® Ventricular Repair System in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF) - The CorCinch-HFrEF Study
    NCT03533517
    Conditions:   Heart Failure;   Cardiomyopathy, Dilated
    Intervention:   Device: AccuCinch® Ventricular Repair
    Sponsor:   Ancora Heart, Inc.
    Recruiting
  • A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis
    NCT03945279
    Condition:   Amyotrophic Lateral Sclerosis
    Interventions:   Drug: BIIB100;   Drug: Placebo
    Sponsor:   Biogen
    Recruiting
  • Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
    NCT03937635
    Condition:   Smoldering Plasma Cell Myeloma
    Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study Utilizing Patient-Reported and Radiographic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
    NCT03928184
    Condition:   Knee Osteoarthritis
    Interventions:   Drug: Lorecivivint;   Drug: Placebo
    Sponsor:   Samumed LLC
    Recruiting
  • Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
    NCT03919994
    Condition:   Schizophrenia
    Intervention:  
    Sponsor:   Alkermes, Inc.
    Recruiting
  • A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
    NCT03915964
    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Baricitinib;   Drug: TNF Inhibitor
    Sponsors:   Eli Lilly and Company;   Incyte Corporation
    Recruiting
  • Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
    NCT03891862
    Condition:   Tardive Dyskinesia (TD)
    Interventions:   Drug: Valbenazine;   Drug: Placebo oral capsule
    Sponsor:   Neurocrine Biosciences
    Recruiting
  • A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
    NCT03887715
    Condition:   Treatment Resistant Depression
    Intervention:   Device: Vagus Nerve Stimulation (VNS)
    Sponsor:   LivaNova
    Recruiting
  • Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
    NCT03872401
    Condition:   Coronary Heart Disease (CHD)
    Interventions:   Drug: Evolocumab;   Drug: Placebo
    Sponsor:   Amgen
    Recruiting
  • Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
    NCT03866382
    Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • CemiplimAb Survivorship Epidemiology
    NCT03836105
    Condition:   Cutaneous Squamous Cell Carcinoma
    Intervention:   Drug: cemiplimab
    Sponsor:   Regeneron Pharmaceuticals
    Recruiting
  • Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
    NCT03822468
    Condition:   Breast Cancer
    Interventions:   Drug: Ribociclib;   Drug: Letrozole or Anastrozole;   Drug: Goserelin
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
    NCT03822351
    Conditions:   Stage III Non-small Cell Lung Cancer;   Unresectable
    Interventions:   Drug: Durvalumab + Oleclumab;   Drug: Durvalumab;   Drug: Durvalumab + Monalizumab
    Sponsor:   MedImmune LLC
    Recruiting
  • A Disease Registry of Patients With Mantle Cell Lymphoma
    NCT03816683
    Condition:   Mantle Cell Lymphoma
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting
  • Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer
    NCT03811015
    Conditions:   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
    NCT03793179
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
    NCT03793166
    Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Sinusitis With or Without the Presence of Nasal Polyps
    NCT03781804
    Condition:   Chronic Sinusitis
    Intervention:   Drug: OPN-375
    Sponsor:   Optinose US Inc.
    Recruiting
  • Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)
    NCT03781791
    Conditions:   Constipation;   Parkinson Disease
    Interventions:   Drug: Active Investigational Treatment ENT-01;   Drug: Placebo Treatment
    Sponsor:   Enterin Inc.
    Recruiting
  • Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
    NCT03768414
    Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
    NCT03742895
    Condition:   Advanced Solid Neoplasms
    Intervention:   Drug: Olaparib
    Sponsors:   Merck Sharp & Dohme Corp.;   AstraZeneca
    Recruiting
  • A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
    NCT03738397
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Upadacitinib (ABT-494);   Drug: Dupilumab;   Drug: Placebo
    Sponsor:   AbbVie
    Recruiting
  • Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
    NCT03738215
    Condition:   Major Depressive Disorder
    Interventions:   Drug: Cariprazine;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)
    NCT03737994
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma
    NCT03727087
    Condition:   Melanoma
    Intervention:   Other: Blood Sample Collection
    Sponsor:   Exact Sciences Corporation
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
    NCT03725202
    Condition:   Giant Cell Arteritis (GCA)
    Interventions:   Drug: Upadacitinib;   Drug: Corticosteroid (CS);   Other: Placebo
    Sponsor:   AbbVie
    Recruiting
  • Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
    NCT03723928
    Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
    Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
    NCT03701282
    Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
    NCT03698019
    Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
    NCT03694002
    Conditions:   Locally Advanced Thymic Carcinoma;   Metastatic Thymic Carcinoma;   Recurrent Thymic Carcinoma;   Unresectable Thymic Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ramucirumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.
    NCT03682705
    Condition:   Rheumatoid Arthritis (RA)
    Interventions:   Drug: Upadacitinib;   Drug: ABBV-105;   Drug: Upadacitinib placebo;   Drug: ABBV-105 placebo
    Sponsor:   AbbVie
    Recruiting
  • National Cardiogenic Shock Initiative
    NCT03677180
    Conditions:   Cardiogenic Shock;   Acute Myocardial Infarction;   STEMI - ST Elevation Myocardial Infarction;   NSTEMI - Non-ST Segment Elevation MI;   Heart Attack
    Intervention:  
    Sponsors:   Henry Ford Health System;   Abiomed Inc.;   Chiesi Farmaceutici S.p.A.
    Recruiting
  • A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
    NCT03675308
    Condition:   Psoriatic Arthritis
    Interventions:   Biological: placebo for rizankizumab;   Biological: risankizumab
    Sponsor:   AbbVie
    Recruiting
  • Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
    NCT03654768
    Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
    NCT03633006
    Condition:   Lung Cancer (Diagnosis)
    Intervention:   Other: Blood Sample Collection
    Sponsor:   Exact Sciences Corporation
    Recruiting
  • M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
    NCT03631706
    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: M7824;   Drug: Pembrolizumab
    Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
    Recruiting
  • Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
    NCT03609216
    Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma
    Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Biological: Pegfilgrastim;   Procedure: Conventional Surgery;   Procedure: Radical Cystectomy;   Other: Chemoradiotherapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
    NCT03584009
    Condition:   Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
    Interventions:   Drug: Venetoclax;   Drug: Fulvestrant
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Real-life Effectiveness of Vortioxetine in Depression
    NCT03555136
    Condition:   Major Depressive Disorder
    Intervention:   Drug: Vortioxetine
    Sponsor:   H. Lundbeck A/S
    Recruiting
  • Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
    NCT03521934
    Condition:   Heart Failure-Type 2 Diabetes Mellitus
    Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
    Sponsor:   Sanofi
    Recruiting
  • ECG Belt for CRT Response
    NCT03504020
    Condition:   Heart Failure
    Intervention:   Device: ECG Belt Research System
    Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
    Recruiting
  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
    NCT03499808
    Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
    Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Reducing Lung CongestIon Symptoms in Advanced Heart Failure
    NCT03499236
    Condition:   Heart Failure
    Interventions:   Device: V-Wave Interatrial Shunt;   Other: Control
    Sponsor:   V-Wave Ltd
    Recruiting
  • Benefits of µCor in Ambulatory Decompensated Heart Failure
    NCT03476187
    Condition:   Heart Failure
    Intervention:   Device: µCor
    Sponsor:   Zoll Medical Corporation
    Recruiting
  • Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
    NCT03473223
    Condition:   Acute Coronary Syndrome
    Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
    Sponsor:   CSL Behring
    Recruiting
  • S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
    NCT03418961
    Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
    NCT03414970
    Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
    Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Hemodynamic-GUIDEd Management of Heart Failure
    NCT03387813
    Conditions:   Heart Failure;   Heart Failure, Systolic;   Heart Failure, Diastolic;   Heart Failure NYHA Class II;   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV;   Heart Failure,Congestive;   Heart Failure With Reduced Ejection Fraction;   Heart Failure With Normal Ejection Fraction;   Heart Failure; With Decompensation
    Intervention:   Device: CardioMEMS™ HF System
    Sponsor:   Abbott Medical Devices
    Recruiting
  • Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
    NCT03373045
    Condition:   Asthma
    Intervention:  
    Sponsors:   AstraZeneca;   Parexel;   MedImmune LLC
    Recruiting
  • Palbociclib in Real World Practice
    NCT03280303
    Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
    Intervention:   Other: non-interventional
    Sponsor:   Pfizer
    Recruiting
  • A Registry for Patients Taking Uptravi
    NCT03278002
    Condition:   Pulmonary Arterial Hypertension
    Intervention:  
    Sponsor:   Actelion
    Recruiting
  • Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
    NCT03259074
    Condition:   Ankylosing Spondylitis
    Interventions:   Biological: Secukinumab;   Biological: GP2017 (adalimumab biosimilar)
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
    NCT03250247
    Conditions:   Deep Vein Thrombosis;   Venous Stasis;   Venous Insufficiency;   Venous Leg Ulcer;   Venous Reflux;   Post Thrombotic Syndrome
    Intervention:   Device: Stents
    Sponsors:   Washington University School of Medicine;   Ontario Clinical Oncology Group (OCOG) - McMaster University;   VasCore - Massachusetts General Hospital;   Mid America Heart Institute - St. Luke's Hospital
    Recruiting
  • Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
    NCT03233711
    Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Other: Patient Observation
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
    NCT03228537
    Conditions:   Biphasic Mesothelioma;   Epithelioid Mesothelioma;   Stage I Pleural Malignant Mesothelioma AJCC v7;   Stage IA Pleural Malignant Mesothelioma AJCC v7;   Stage IB Pleural Malignant Mesothelioma AJCC v7;   Stage II Pleural Malignant Mesothelioma AJCC v7;   Stage III Pleural Malignant Mesothelioma AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Cisplatin;   Procedure: Extrapleural Pneumonectomy;   Drug: Pemetrexed Disodium;   Procedure: Pleurectomy;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
    NCT03813238
    Condition:   Cerebral Palsy, Dyskinetic
    Interventions:   Drug: Deutetrabenazine;   Drug: Placebo
    Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
    Recruiting
  • Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
    NCT03087708
    Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure
    NCT03035474
    Condition:   Heart Failure
    Interventions:   Other: Digital Engagement;   Other: Direct Engagement
    Sponsors:   Duke University;   Duke Clinical Research Institute
    Recruiting
  • Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
    NCT03033576
    Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
    NCT02993406
    Conditions:   Cardiovascular Diseases;   Statin Adverse Reaction
    Interventions:   Drug: Bempedoic acid 180 mg tablet;   Drug: Matching placebo tablet
    Sponsors:   Esperion Therapeutics;   The Cleveland Clinic
    Recruiting
  • Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
    NCT02947347
    Condition:   Treatment Naive Follicular Lymphoma
    Interventions:   Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: rituximab
    Sponsor:   Pharmacyclics LLC.
    Recruiting
  • Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
    NCT02923726
    Condition:   Sudden Cardiac Death
    Interventions:   Device: Arm 1 (ATP+Shock);   Device: Arm 2 (shock only)
    Sponsors:   Boston Scientific Corporation;   ICON plc
    Recruiting
  • Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
    NCT02912559
    Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
    NCT02793583
    Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
    Sponsor:   TG Therapeutics, Inc.
    Recruiting
  • The PARTNER 3 - Trial - The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis
    NCT02675114
    Condition:   Aortic Stenosis
    Interventions:   Procedure: Surgical aortic valve replacement (SAVR);   Device: Transcatheter Aortic Valve Replacement (TAVR)
    Sponsor:   Edwards Lifesciences
    Recruiting
  • An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
    NCT02623699
    Condition:   Amyotrophic Lateral Sclerosis
    Interventions:   Drug: BIIB067;   Other: Placebo
    Sponsors:   Biogen;   Ionis Pharmaceuticals, Inc.
    Recruiting
  • Dimethyl Fumarate (DMF) Observational Study
    NCT02047097
    Condition:   Multiple Sclerosis
    Intervention:   Drug: dimethyl fumarate
    Sponsor:   Biogen
    Recruiting
  • Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
    NCT01996865
    Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Lenalidomide;   Drug: Rituximab
    Sponsor:   Celgene
    Recruiting
  • Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
    NCT01896999
    Conditions:   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
    NCT03204916
    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Connect® MDS/AML Disease Registry
    NCT01688011
    Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
    Intervention:  
    Sponsor:   Celgene
    Recruiting
  • Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
    NCT03067181
    Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Multi-Institutional Registry for Prostate Cancer Radiosurgery
    NCT01226004
    Conditions:   Prostate Cancer Early Risk Treated by Radiosurgery;   Prostate Cancer Intermediate Risk Treated by Radiosurgery
    Intervention:  
    Sponsor:   Florida Robotic Radiosurgery Association
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
    NCT03769090
    Condition:   Asthma
    Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
    Sponsor:   Bond Avillion 2 Development LP
    Recruiting
  • A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
    NCT03661866
    Conditions:   Atopic Dermatitis;   Alopecia;   Hidradenitis Suppurativa;   Vitiligo;   Psoriasis
    Intervention:  
    Sponsor:   Target PharmaSolutions, Inc.
    Recruiting
  • Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
    NCT03633617
    Condition:   Eosinophilic Esophagitis
    Interventions:   Drug: Dupilumab;   Drug: Placebo
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • Axitinib and Nivolumab in Treating Patients With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma
    NCT03595124
    Conditions:   Metastatic Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Axitinib;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Long Term Safety Study of BCX7353 in Hereditary Angioedema
    NCT03472040
    Conditions:   Hereditary Angioedema;   HAE;   Prophylaxis
    Intervention:   Drug: BCX7353
    Sponsor:   BioCryst Pharmaceuticals
    Recruiting
  • Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
    NCT03428646
    Condition:   Dermatitis, Atopic
    Intervention:   Drug: Dupilumab
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
    NCT03148418
    Condition:   Cancer
    Intervention:   Drug: Atezolizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • OPsumit USers Registry
    NCT02126943
    Condition:   Pulmonary Arterial Hypertension
    Intervention:   Drug: Opsumit (macitentan)
    Sponsor:   Actelion
    Recruiting
  • Product Surveillance Registry
    NCT01524276
    Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
    Intervention:  
    Sponsor:   Medtronic
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC